off-the-shelf

Adapting cell therapies to solid tumors 2:57
Adapting cell therapies to solid tumors
Nina Bauer • 26 Jan 2022
The advantages and applications of CRISPR-Cas 9 1:47
The advantages and applications of CRISPR-Cas 9
Nina Bauer • 27 Jan 2022
Advantages of allogeneic NK cell therapy 2:26
Advantages of allogeneic NK cell therapy
Kanya Rajangam • 13 Oct 2021
Developments in NK cell therapy 2:48
Developments in NK cell therapy
Kanya Rajangam • 13 Oct 2021
Treating hematologic malignancies with immunotherapy 0:59
Treating hematologic malignancies with immunotherapy
Kanya Rajangam • 13 Oct 2021
Advances in cell-based therapies for MS 4:55
Advances in cell-based therapies for MS
Jakob Dupont • 17 Jun 2021
ATA188: an allogeneic EBV-specific T cell therapy for progressive MS 5:20
ATA188: an allogeneic EBV-specific T cell therapy for progressive MS
Jakob Dupont • 17 Jun 2021
Characterization of ATA188: an off-the-shelf therapy for MS 4:08
Characterization of ATA188: an off-the-shelf therapy for MS
Jakob Dupont • 17 Jun 2021
Allogenic NKX101 in r/r AML 2:56
Allogenic NKX101 in r/r AML
James Trager • 22 Feb 2021
Universal “off-the-shelf” CAR T-cells from iPSCs 4:58
Universal “off-the-shelf” CAR T-cells from iPSCs
Alexandros Nianias • 6 Feb 2021
The content of VJRegenMed is intended for healthcare professionals